Evaluation of Safety and Efficacy of Lumason in Pediatric Echocardiography

Bracco

Status and phase: Terminated; Phase 3

Conditions: Heart Disease

Treatments: Drug: sulphur hexafluoride lipid-type A microspheres

Study type: Interventional

Funder types: Industry

Identifiers

NCT02282163

BR1-140

Details and patient eligibility

About

Safety and Efficacy Study in pediatric subjects aged 9 to 17 years of age with suboptimal LV EBD on non-contrast 2D echocardiography. Imaging modalities that are used throughout the study in pediatric subjects represented those utilized in routine clinical practice in adults.

Full description

This was a Phase III, multicenter, open-label study that was to be conducted at approximately 7-12 sites in the United States, Canada and Europe in pediatric patients with suboptimal LV EBD on non-contrast 2D transthoracic echocardiography. It was estimated that 92 patients were to be enrolled to provide 73 evaluable patients.

Three cardiologists unaffiliated with enrolling centers (blinded readers), blinded to the patient's identity and clinical profile were to independently evaluate the echocardiograms. The efficacy analysis was primarily based on the blinded reader evaluations.

Imaging modalities that are used throughout the study in pediatric subjects represented those utilized in routine clinical practice in adults.

One of the sites participating in this study was to be asked to consent a subset of patients for additional blood sampling for analysis of SF6 concentration in blood from a total of 6 patients (3 males and 3 females) in the age group 9 up to 12 years of age and 6 patients (3 males and 3 females) in the age of >12 up to and including 17 years.

The current study was designed to assess the efficacy of Lumason-enhanced echocardiography in pediatric patients.

Enrollment: 13 patients

Sex: All

Ages: 9 to 17 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Provide Written informed consent from parent(s) or legal guardian
• Provide assent when required according to local regulations
• Suspected of having cardiac disease or undergoing evaluation of cardiac anatomy for congenital heart disease
• Undergone a previous transthoracic echocardiogram within one month prior to enrollment resulting in suboptimal left ventricular endocardial border defined as ≥ 2 contiguous segments in any given view that cannot be visualized.

Exclusion criteria

• Children < 9 years of age
• Previously enrolled in the study
• Administered any other contrast agent either intravascularly or orally within 48 hours of Lumason administration
• Known right-to-left, bidirectional or transient cardiac shunt (ruled out with agitated saline study performed before administration of Lumason)
• Known hypersensitivity to one or more of the ingredients of the investigational product
• Received an investigational compound within 30 days before enrolling into this study
• Pregnant or lactating female
• Determined by investigator to be unsuitable for the study

Trial design

Primary purpose: Diagnostic

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

13 participants in 1 patient group

Lumason

Experimental group

Description:

All patients were administered, Lumason (sulphur hexafluoride lipid-type A microspheres) an ultrasound contrast agent as a single 0.03 mL/kg bolus injection during echocardiography.

Treatment:

Drug: sulphur hexafluoride lipid-type A microspheres